fr   en

Tableaux synoptiques (en anglais)

Parcourir par date
Rechercher par mot clé
Date: 2008-12-17
Company: Prosensa Holding (The Netherlands)
Investors: GIMV (Belgium) AGF Private Equity (France) LSP (The Netherlands) Abingworth (UK) MedSciences Capital
Amount: €18 million
Planned use: This series B round will be used to develop its two lead programs, in the field of Duchenne muscular dystrophy (DMD),
Other: Prosensa Holding is focused on RNA interference therapeutics using exon skipping technology. Prosensa's technology uses oligoribonucleotides to restore production of dystrophin, the protein defective in DMD patients. These oligonucleotides are designed to remove an unwanted segment of the faulty DMD gene product.